Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $71.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 24.04% year-over-year to $71.1 million; the TTM figure through Mar 2026 stood at $71.1 million (up 24.04% YoY), while the FY2025 annual figure was $85.1 million, up 42.54% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $71.1 million, down from $85.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $85.1 million in Q4 2025, with the low at $20.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $51.8 million (2024), against an average of $48.1 million.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 119.1% in 2022, then gained 10.71% in 2025.
• Crinetics Pharmaceuticals' Total Current Liabilities stood at $27.7 million in 2022, then soared by 58.5% to $43.9 million in 2023, then surged by 35.82% to $59.7 million in 2024, then soared by 42.54% to $85.1 million in 2025, then retreated by 16.44% to $71.1 million in 2026.
• Business Quant data shows CRNX's Total Current Liabilities at $71.1 million in Q1 2026, $85.1 million in Q4 2025, and $74.2 million in Q3 2025.